MiR-361-5p inhibits the glycolysis and invasion of breast cancer cells by respectively targeting MMP-1 and fibroblast growth factor receptor 1 (FGFR1), which is a promoter of glycolytic enzyme and a suppresser of OXPHOS (oxidative phosphorylation) (39). Here, FGFR1 is linked to breast cancer.